Molecular testing on the primary tumor was requested; no mutations were noted in KRAS, NRAS, BRAF, PIK3CA (quadruple wild type) and the tumor was microsatellite stable (MSS)
Chest, abdominal, and pelvic CT scan showed small bilateral lung nodules, a 3-cm mass in the right lobe of the liver, and a mass in the sigmoid colon measuring 10 cm
Diagnosis, unresectable metastatic colorectal cancer
Treatment was initiated with FOLFIRI + cetuximab and he appeared to respond well
CT scans at 3 and 6 months showed decreased size of liver and lung nodules
August 2015
The patient complained of increased fatigue, and reported needing frequent breaks while performing daily activities
CT scan showed increased size of the liver nodule (to 4 cm) and the appearance of 4 new small liver lesions (<2 cm)
He began therapy with FOLFOX + bevacizumab
March 2016
The patient complained of severe fatigue
CT scan revealed progressive disease with no improvement in the primary and metastatic lesion size and/or number
A new pulmonary nodule was seen in the right lung
He was then started on trifluridine/tipiracil
PET/CT at 3 months showed stable disease
At 6-months, he reported less fatigue and some improvement in performing daily tasks
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.